News & Updates

Treatment with the anti-interleukin-23p19 inhibitor mirikizumab led to significant improvements in patient-assessed disease severity and activity, as well as abdominal pain, in individuals with moderate-to-severe active Crohn’s disease, according to phase II data presented at the Crohn’s and Colitis Congress (CCC) 2022.

In children with Crohn’s disease with sustained clinical and deep remission, cessation of azathioprine (AZA) does not seem to lead to an excess risk of relapse, a recent study has found. In contrast, discontinuation of infliximab does entail such a risk.

In colon cancer patients receiving curative surgery, undergoing haemodialysis still carries a high risk of postoperative complications despite advancements in perioperative management, a recent study has found.

Surgical feeding ostomies (eg gastrostomy) result in significantly higher in-hospital adverse event rates than natural orifice (eg, nasogastric or orogastric) feeding tubes, a study has shown. Thus, policies that require surgical feeding ostomies must be re-evaluated.

A recent study has discovered inappropriate use of faecal immunochemical testing (FIT) in emergency and inpatient settings. Moreover, FIT has led to more gastroenterology consultations but is not independently associated with inpatient endoscopy.